Mochida receives an approval for an Anti-depressant, Lexapro® 10 mg in Japan

Mochida Pharmaceutical Co., Ltd.

(Tokyo, April 22, 2011) Mochida Pharmaceutical Co., Ltd. (Head office: Tokyo, Japan, President: Naoyuki Mochida, hereinafter: Mochida) today announced that the company received the approval of market authorization for Lexapro® 10 mg (generic name: escitalopram) by the Japanese Ministry of Health, Labour and Welfare (MHLW).

Lexapro® is a selective serotonin reuptake inhibitor, originally discovered by H. Lundbeck A/S (Head office: Copenhagen, Denmark, CEO: Ulf Wiinberg), and is available in more than 90 countries with a good record of achievement since it was launched as Cipralex® in European countries and Lexapro® in the United States in 2002. In Japan, Mochida has contracted with Lundbeck and has conducted the development of Lexapro®. Mochida hopes that Lexapro® will contribute to improving QOL of the patients with depression as a new therapeutic option.

Mochida and Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, Japan, President & CEO: Michihiro Tsuchiya, hereinafter: Mitsubishi Tanabe Pharma) will co-market the product, and Yoshitomiyakuhin Corporation (Head Office: Osaka, Japan, President & CEO: Yoshikazu Nakao), a subsidiary of Mitsubishi Tanabe Pharma, will participate in the promotion. The schedule for the launch of Lexapro® will be announced after its National Health Insurance price listing.

Contacts for inquiries:
Public Relations, Mochida Pharmaceutical Co., Ltd.
E-mail webmaster@mochida.co.jp